Key result
Sacubitril-valsartan was a cost-effective treatment option for HFrEF in China compared to enalapril, yielding an incremental cost-effectiveness ratio of $2,480.67 per QALY gained.
Why the study?
Sacubitril-valsartan is a guideline-recommended treatment for HFrEF, but its cost-effectiveness compared with enalapril had not been evaluated in China.
Is sacubitril-valsartan cost-effective compared to enalapril for the treatment of HFrEF in China?
Is sacubitril-valsartan cost-effective compared to enalapril for the treatment of HFrEF in China?
Sacubitril-valsartan is a highly cost-effective treatment option for HFrEF in China compared to enalapril over a 10-year horizon.
Answers are grounded in this paper and cite their sources.
May support Sac-Val consideration for HFrEF in China; leaves open prospective validation in local cohorts.
OBJECTIVES: Heart failure with reduced ejection fraction (HFrEF) is a major health concern globally due to high mortality rates, frequent hospitalization and considerable medical expenditure. The prevalence of HFrEF is steadily rising in Asian countries, and populous, developing countries like China are facing a significant socio-economic burden as a result. Sacubitril-valsartan (Sac-Val) is currently a class I recommendation for treating HFrEF in major guidelines, although it has not been pharmaco-economically evaluated in China. To this end, we compared the cost-effectiveness of Sac-Val and enalapril based on the negotiated prices in order to fully assess the expected costs and benefits of the clinical use of Sac-Val in China. METHOD: A Markov model was constructed to estimate long-term clinical and economic outcomes of Sac-Val versus enalapril for HFrEF patients in China over a 10-year horizon. Primary model outcomes were total costs and quality-adjusted life years (QALYs), and the incremental cost-effectiveness ratio (ICER). RESULTS: Treatment with Sac-Val resulted in 4.67 QALYs at the cost of $4,684.25, while enalapril yielded 4.40 QALYs at the cost of $4,014.47. Compared to enalapril, Sac-Val was associated with a gain of 0.27 QALYs, resulting in an ICER of $ 2,480.67 per QALY. Deterministic sensitivity analysis showed robust results. Probabilistic sensitivity analysis suggested that Sac-Val has a 99.99% probability of being cost-effective at the willingness-to-pay threshold of $10,276. CONCLUSION: From Chinese patients' perspective, Sac-Val is a cost-effective treatment option for HFrEF in China compared to enalapril. Our findings can aid clinicians plan the Sac-Val regimen, as well as decision makers to discuss the value and position of novel angiotensin receptor neprilysin inhibitors (ARNIs) in future.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2020) studied Heart failure with reduced ejection fraction (HFrEF). Sacubitril-Valsartan vs. Enalapril was evaluated on Incremental cost-effectiveness ratio (ICER) per quality-adjusted life year (QALY) gained (ICER $2,480.67 per QALY). Sacubitril-valsartan was a cost-effective treatment option for HFrEF in China compared to enalapril, yielding an incremental cost-effectiveness ratio of $2,480.67 per QALY gained.
Synapse has enriched 10 related papers. Consider them for comparative context: